ISAKOS: 2023 Congress in Boston, MA USA

2023 ISAKOS Biennial Congress ePoster

 

Evaluation Of Different Commercial Hyaluronic Acids As A Vehicle for Injection of Human Adipose-Derived Mesenchymal Stem Cells

José Ricardo Dantas Moura Costa, MD, São Paulo, São Paulo BRAZIL
Nathalia Bofill Burger, Uruguaiana, Rio Grande do Sul BRAZIL
Marcel Henrique Arcuri, Md, Sao Paulo BRAZIL
Diego Costa Astur, MD, PhD, São Paulo, SP BRAZIL
Camila Cohen Kaleka, PhD, São Paulo, SP BRAZIL
Pedro Debieux, MD, PhD, São Paulo, SP BRAZIL
Moises Cohen, MD, PhD, Prof., São Paulo, SP BRAZIL

Hospital Israelita Albert Einstein, São Paulo, São Paulo, SP, BRAZIL

FDA Status Not Applicable

Summary

After valuation of different commercial hyaluronic acids, ehese data suggest that hyaluronic acid can be used as a vehicle for injection of human AD-MSCs.

ePosters will be available shortly before Congress

Abstract

Objective

The main purpose of this study is to evaluate, in vitro, the cytotoxicity of different commercial brands of hyaluronic acids to be used as a vehicle for injection of human adipose-derived mesenchymal stem cells (AD-MSCs).

Methods

AD-MSCs were divided into seven groups: one control group where AD-MSCs were cultivated with phosphate-buffered saline (PBS) and six other groups where AD-MSCs were cultivated with different commercial brands of hyaluronic acid. AD-MSC viability analysis was performed after 4, 24, and 48 h in contact with each treatment, using the trypan staining method on a Countess automated cell counter (Thermo Fisher Scientific).

Results

The results clearly demonstrated a significant difference in cell viability when AD-MSCs were exposed to different hyaluronic acids when compared with the control group.

Conclusion

These data suggest that hyaluronic acid can be used as a vehicle for injection of human AD-MSCs, but caution is needed to choose the best product, aiming at its future therapeutic application.